Roivant Sciences Ltd. (ROIV)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $38.71
- As of
Kresmion compiles this page from ROIV's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Roivant Sciences Ltd. (ROIV): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-09.
See the full ROIV dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ROIV on one page. Preview it with sample data, then open it live with a free account.
Preview the ROIV dossierActive events for ROIV
- high13F: funds added
4 tracked funds increased ROIV this 2026Q2, institutional consensus
- high13F: large reduction
CITADEL ADVISORS LLC cut 68% of ROIV (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 57% of ROIV (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +1654% to ROIV (2026Q2)
- high13F: large reduction
Point72 Asset Management, L.P. cut 86% of ROIV (2026Q2)
FREE, NO ACCOUNT
Every event on ROIV, as it fires
You are seeing 5 of 15 events recorded on ROIV since 2026-05-27.
The five above landed across 2 days. The other 10 were recorded on 4 other days. 10 of the 15 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, ROIV
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on ROIV
ROIV against its peers
ROIV's operating margin of -6235.7% ranks in the 3rd percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | ROIV | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 8.3M USD | 2.3B USD | 13 | 18 |
| Gross margin | n/a | 86.8% | n/a | 15 |
| Operating margin | -6235.7% | 13.1% | 3 | 18 |
| Net margin | -3629.2% | 10.8% | 3 | 19 |
| Return on equity | -6.6% | 7.1% | 33 | 19 |
| P / E | n/a | 32.2x | n/a | 9 |
| 1 year | 89.8% | 21.8% | 88 | 20 |
Peers (22): INSM, RPRX, UTHR, GMAB, INCY, RVMD, ALNY, BNTX, BIIB, NTRA, ASND, NBIX, ONC, EXEL, BBIO, ARGX, BMRN, HALO, KYMR, APGE.D, MDGL, NUVL.D. Left out: IVBXF (no annual filing), CSLLY (no annual filing), SBMFF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (ROIV: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in ROIV on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on ROIV in the last 180 days.
Upstream: SEC EDGAR filings for ROIV
Kresmion, "Roivant Sciences Ltd. (ROIV) institutional holdings and SEC filings", data as of 2026-11-09, https://kresmion.com/research/ROIV. Upstream data: SEC EDGAR filings for ROIV.
Link to this data (HTML):
<a href="https://kresmion.com/research/ROIV">Roivant Sciences Ltd. (ROIV) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow ROIV on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to ROIV for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.